
The U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) launched the New Approach Methodologies (NAMs) Database of Use Case Examples on November 19, 2026, establishing the first federal repository of non-animal testing models accepted in human drug evaluations. The initiative provides academic investigators, university technology transfer offices, and translational research teams with practical evidentiary precedents for replacing, reducing, and refining vertebrate animal testing in regulatory submissions.
FDA CDER Streamlined Nonclinical Studies and NAMs Repository Launch
On November 19, 2026, the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research introduced its New Approach Methodologies (NAMs) Database of Use Case Examples under the CDER Streamlined Nonclinical Studies program. The repository compiles non-animal testing approaches extracted from public FDA review summaries for approved small-molecule drugs and therapeutic biological products.
The system addresses a longstanding barrier in drug development: while federal statutes permit alternative nonclinical methods, sponsors often lacked transparency into which specific testing packages and validation thresholds CDER reviewers accept. By organizing entries by testing methodology, the platform links accepted alternative methods to specific drug applications, toxicological endpoints, and organ systems where they satisfied statutory requirements.
Each entry connects directly to the Collection of Alternative Methods for Regulatory Application (CAMERA) database, maintained by the National Institutes of Health and the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods. CAMERA provides standard operating procedures and validation records, while CDER’s database establishes regulatory context of use across approved drug dossiers.
Cataloged Alternative Methodologies and Regulatory Use Cases
The CDER repository encompasses four core technical categories: reconstructed human tissues, microphysiological systems (MPS), in chemico testing, and in silico computational pharmacology. Across these categories, records illustrate where non-animal data supported pivotal conclusions or allowed sponsors to waive specific animal cohorts.
For early-stage pipelines, the catalog establishes benchmarks for designing IND-enabling studies without defaulting to legacy animal protocols. The database documents instances where human-derived models provided mechanistic clarity that traditional species models could not replicate, particularly in target engagement, human metabolite profiling, and hypersensitivity.
The following table summarizes primary New Approach Methodologies in the repository, their technical platforms, accepted regulatory endpoints, and animal models replaced or refined:
| NAM Category | Representative Platforms | Accepted Regulatory Endpoints | Traditional Model Replaced or Refined |
|---|---|---|---|
| Reconstructed Human Tissue | EpiDerm SIT, EpiSkin RhE assays (OECD TG 439) | Dermal irritation, corrosion, and transdermal permeability | Rabbit Draize dermal irritation testing |
| Ex Vivo Corneal Assays | Bovine Corneal Opacity/Permeability (BCOP, OECD TG 437), Corrositex | Ocular irritation, mucosal tolerance, toxicity classification | Rabbit Draize eye irritation test |
| In Chemico & Cellular Sensitization | Direct Peptide Reactivity Assay (DPRA), KeratinoSens (OECD TG 442C/D) | Skin sensitization, haptenation kinetics, dendritic activation | Guinea pig maximization test, murine Local Lymph Node Assay (LLNA) |
| Microphysiological Systems (MPS) | Human liver-on-a-chip, microfluidic vascular barriers | Mechanistic drug-induced liver injury (DILI), barrier transport | Subchronic rodent and non-rodent repeat-dose toxicology cohorts |
| In Silico Predictive Toxicology | Rule-based (Derek) and statistical QSAR models (Leadscope) | Bacterial mutagenicity, drug impurity qualification (ICH M7) | Rodent Ames bioassay and in vivo micronucleus testing |
The FDA emphasized that database listings serve illustrative purposes and do not guarantee automatic acceptance. Every submission remains subject to context-of-use evaluation under 21 CFR Part 58 GLP requirements and nonclinical testing standards, requiring sponsors to demonstrate assay reproducibility and biological relevance.
Regulatory Modernization and Legislative Architecture
The repository operationalizes congressional mandates enacted under the FDA Modernization Act 2.0 and the Food and Drug Omnibus Reform Act of 2022 (FDORA). These statutes amended Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) to replace mandatory animal testing references with technologically neutral terminology, authorizing sponsors to support drug safety with qualified nonclinical models.
To implement this change, the agency issued a Direct Final Rule in the Federal Register on Nonclinical Testing Terminology, amending 21 CFR Parts 312, 314, 315, 361, and 601. The rule replaced legacy terms such as “animal test” and “preclinical” with standardized definitions for “nonclinical test” and “nonclinical study,” formally incorporating in vitro assays, microphysiological systems, and in silico models.
This structural change applies across the regulatory continuum, from the initial Investigational New Drug (IND) filing to the safety summaries required for a New Drug Application (NDA). In reviewing an IND vs NDA package, FDA toxicologists evaluate whether the nonclinical evidence characterizes toxicokinetics, off-target liabilities, and first-in-human starting dose safety margins, regardless of whether data originated from animal models or validated microfluidic systems.
Scientific Community and Industry Stakeholder Reaction
The launch drew positive reactions from pharmaceutical researchers and translational societies. In an analysis published by the American Association of Pharmaceutical Scientists Translational and Clinical Science Community, researchers welcomed the database as an essential step to resolve regulatory hesitancy. The community noted that while developers have created sophisticated organ-on-a-chip systems, uncertain agency acceptance previously prompted sponsors to conduct redundant animal studies in parallel.
Regulatory affairs specialists noted that transparency regarding approved precedents accelerates adoption of human-relevant safety tools. In an evaluation of alternative nonclinical frameworks, the Regulatory Affairs Professionals Society noted that documented regulatory use cases provide the empirical basis developers need to justify alternative testing packages. RAPS analysts emphasized that documented examples assist sponsors in structuring fit-for-purpose qualification data.
Advocacy groups supporting the 3Rs (Replacement, Reduction, and Refinement) observed that public documentation of accepted alternatives prevents needless repetition of vertebrate studies across therapeutic classes, noting that human cellular systems frequently provide higher predictive fidelity for human organ toxicity than animal models.
Implications for Academic Labs, Universities, and Research Offices
The availability of accepted nonclinical use cases carries immediate operational consequences for university research administration and translational programs:
Translational Pipeline Design
Principal investigators designing drug-screening protocols can incorporate validated NAMs into grant proposals with documented regulatory backing. Federal grant reviewers increasingly favor human-derived microphysiological models, and citing FDA acceptance of specific platforms strengthens translational study designs.
IACUC Protocol Review
Under the Animal Welfare Act and Public Health Service Policy, Institutional Animal Care and Use Committees (IACUCs) must ensure investigators consider non-animal alternatives. Documented FDA use cases give committees and attending veterinarians concrete benchmarks to question redundant animal cohorts when validated in vitro or in silico assays exist.
Technology Transfer and Licensing
For technology transfer offices and university spin-offs, drug-discovery assets supported by robust human-relevant NAM data offer cleaner regulatory profiles. Human organoid and microfluidic data reduce early clinical attrition risks, supporting asset valuation during licensing and venture discussions.
Pre-IND Division Consultations
University researchers advancing novel therapeutics should utilize early FDA meeting mechanisms. Requesting an FDA Pre-IND meeting allows academic sponsors to present non-animal testing plans directly to CDER review divisions, citing repository use cases to build regulatory alignment before committing funds to toxicology studies.
Regulatory Milestones and Next Steps for Drug Sponsors
The regulatory transition to New Approach Methodologies follows defined federal timelines. Public comments on the Direct Final Rule on Nonclinical Testing Terminology close on December 7, 2026. Unless significant adverse comments lead to withdrawal, the direct final rule takes legal effect on February 4, 2027.
CDER plans to expand the database as additional non-confidential review summaries become available. The agency is also advancing qualification through the Innovative Science and Technology Approaches for New Drugs (ISTAND) pilot program, which evaluates novel methodologies intended for broad regulatory application across multiple drug programs.
Research institutions and biopharmaceutical developers preparing 2027 regulatory submissions are advised to benchmark nonclinical assay choices against both the CDER database and NIH CAMERA records, engaging early with review divisions to confirm proposed testing packages satisfy statutory safety requirements.
Sources
- U.S. Food and Drug Administration: New Approach Methodologies (NAMs) Database of Use Case Examples, checked 2026-11-22
- National Institutes of Health: CAMERA — Collection of Alternative Methods for Regulatory Application, checked 2026-11-22
- American Association of Pharmaceutical Scientists: FDA Final Rule, Proposed Rule and NAMS database News Release, checked 2026-11-22
- Federal Register: Nonclinical Testing Terminology (Direct Final Rule, 91 FR 19350), checked 2026-11-22
- Regulatory Affairs Professionals Society: FDA drafts guidance on animal testing alternatives, checked 2026-11-22







